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Abstract 44 
Background: Movement disorders (MD) associated with exposure to antipsychotic drugs (AP-45 
MD) are common and stigmatising, but underdiagnosed.  46 
Methods: We developed a screening procedure for AP-MD for administration by mental health 47 
(MH) nurses. Item selection and content validity assessment were conducted by a panel of 48 
neurologists, psychiatrists and a MH nurse, who operationalised a 31-item screening procedure 49 
(ScanMove instrument). Inter-rater reliability was measured on ratings from ten MH nurses 50 
evaluating video-recordings of the procedure on 30 patients with psychosis. Criterion and 51 
concurrent validity were tested comparing the ScanMove instrument-based rating of thirteen MH 52 
nurses of 635 community patients from MH services to diagnostic judgement of a MD 53 
neurologist based on the ScanMove instrument and a reference procedure comprising a selection 54 
of commonly used rating scales. 55 
Results: Inter-reliability analysis showed no systematic difference between raters in their 56 
prediction of any AP-MD category. On criterion validity testing, the ScanMove instrument 57 
showed good sensitivity for parkinsonism (94%) and hyperkinesia (89%), but not for akathisia 58 
(38%), whereas specificity was low for parkinsonism and hyperkinesia, and moderate for 59 
akathisia. Mixed effect regression models showed low concurrent validity of quantitative scores 60 
obtained from the ScanMove instrument. 61 
Conclusions: The ScanMove instrument demonstrated good feasibility and inter-rater reliability, 62 
and acceptable sensitivity as MH nurse-administered screening tool for parkinsonism and 63 
hyperkinesia.  64 
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 68 
Introduction 69 
Long-term treatment with antipsychotic medication of patients with an established psychotic 70 
illness can cause a range of hypokinetic and hyperkinetic movement disorders. Parkinsonism and 71 
akathisia may occur shortly after the beginning of antipsychotic exposure, and may last 72 
indefinitely if the exposure continues. Delayed-onset (or tardive) movement disorders associated 73 
with antipsychotics comprise a spectrum of abnormal movements cumulatively labeled as tardive 74 
dyskinesia, and tardive akathisia.
1,2
 These usually appear after many months or years of drug 75 
treatment, and often do not abate completely, or may even worsen, after treatment withdrawal.
1,2
 76 
Antipsychotic-associated movement disorders may cause social stigma and impact on quality of 77 
life.
12-20 
78 
The prevalence of tardive dyskinesia from trials and naturalistic studies ranges between 79 
13.1% for second generation antipsychotics and 32.4% for first generation antipsychotics.
3-10
 The 80 
prevalence of other movement disorders across reports ranges between 23% and 65% for 81 
parkinsonism, and between 15% and 30% for akathisia.
8,9,11
 The lower prevalence of movement 82 
disorders reported with some of the newer antipsychotics has probably contributed to diminished 83 
awareness amongst health professionals. 84 
Movement disorders in established psychosis are still under-recognised. Within a quality 85 
improvement programme, a national audit of specialist mental health provider organisations in 86 
the UK in 2008 reported that, despite existing national clinical guidelines, 69% of 5,804 patients 87 
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receiving depot/long-acting antipsychotic preparations were not assessed at all for movement 88 
disorders in the previous year, and only 4% had been formally evaluated for these 89 
manifestations.
21
 This performance improved only in part following educational interventions, 90 
suggesting that other factors, besides limited awareness, play a role in shaping health 91 
professionals’ attitude towards movement disorders monitoring. In particular, a sufficiently brief 92 
and reliable instrument for their systematic screening is lacking. The most popular instruments 93 
available in routine clinical practice are validated multiple-item severity rating scales.
22-25
 94 
Although their use has been adapted for screening purposes, these may be considered too long to 95 
administer together.
26
  96 
Although their role within primary and secondary mental health services is still 97 
debated,
27,28
 registered mental health nurses provide a crucial contribution to long-term care, 98 
including the provision of psychosocial interventions and health promotion for patients in both 99 
inpatient and outpatient settings.
29
 This specific activity has been under-explored in mental 100 
health nurses, although their involvement in side effect screening for long-term antipsychotics 101 
could represent a cost-effective strategy.  102 
In this study, we present the development and initial clinimetric evaluation of a new 103 
clinical procedure, the ScanMove instrument, for the screening of antipsychotic-associated 104 
movement disorders performed by mental health nurses on patients with established psychosis 105 
from community services. 106 
 107 
Methods 108 
Development of the ScanMove instrument 109 
The ScanMove instrument was developed by a panel of four neurologists, four psychiatrists, and 110 
Page 5 of 26
Cambridge University Press
BJPsych Open
For Peer Review
Screening antipsychotic-associated movement disorders 
5 
 
one mental health [MH] nurse with expertise in movement disorders (MD) associated with 111 
antipsychotics. The panel formulated an initial list of diagnostically relevant clinical features of 112 
parkinsonism, hyperkinesia (encompassing all types of involuntary movements) and akathisia, 113 
based on clinical experience and critical review of existing rating scales. Panelists judged each 114 
feature as essential or not essential for the diagnosis of MD, based on the following questions: 115 
“does this feature help substantially in the diagnosis?”, “is the assessment of this feature 116 
sufficiently reliable, feasible and effective to be applied on large clinical scale?”. The content 117 
validity of each feature was measured calculating the content validity ratio (CVR) as follows: 118 
CVR=(ne-N/2)/(N/2), where ne is the number of raters judging the feature as “essential”, and N is 119 
the total number of raters. All features with CVR>0.75 passed content validity assessment at the 120 
first round and were included in the instrument. A second round of discussion focused on 121 
features with CVR between 0.5 and 0.75, leading by consensus to a final decision of 122 
inclusion/exclusion.  123 
The ScanMove instrument was then operationalised defining type and sequence of the 124 
clinical manoeuvres required to assess the selected features, structuring a procedure that could be 125 
administered within 15 minutes. The assessment of each clinical feature led to one of three 126 
possible judgements: ‘yes’, ‘no’, ‘unsure’.   127 
Training of raters 128 
Thirteen registered MH nurses experienced in mental illnesses in inpatient or community 129 
services were trained in the ScanMove instrument through three half-day interactive sessions run 130 
by two MD neurologists (DM, KPB). The first session provided an overview of the 131 
phenomenology of antipsychotics-associated MD using historical patient video-recordings. In the 132 
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other two small group sessions, trainers and trainees reviewed video-recordings of the instrument 133 
administration to 20 community psychiatric patients.   134 
Reliability assessment 135 
Thirty adult patients with consenting capacity from community services within three NHS MH 136 
trusts in North and West London were recruited for inter-rater reliability testing, enrolling 137 
eligible patients consecutively. Inclusion criteria were: i) one of the following DSM-V 138 
diagnoses: schizophrenia, schizophreniform disorder, schizoaffective disorder, or delusional 139 
disorder; ii) documented exposure for >3 months to >1 antipsychotic drug; iii) having an 140 
allocated care co-ordinator within a community rehabilitation team or residential service; iv) 141 
absence of neurological diagnoses causing MD. All patients were administered the ScanMove 142 
instrument by the evaluating neurologist (BB). The assessment was recorded using the same 143 
videocamera and audiovisual settings. Ten trained MH nurses rated the video-recordings 144 
compiling the ScanMove instrument summary sheet. Ratings provided an aggregated score (1 145 
point per item) and a dichotomus judgement (>1 item= presence) separately for parkinsonism, 146 
hyperkinesia and akathisia.  147 
Criterion and concurrent validity assessment 148 
Patients from the same community services were selected with the same criteria, and underwent 149 
a single study visit. Sociodemographic data, psychiatric diagnoses and information on 150 
medication exposure during the previous year were collected for each participant by one of the 151 
trained MH nurses. Subsequently, the same nurse administered the ScanMove instrument. After 152 
a brief intermission, the evaluating MD neurologist used the same clinical manouevres applied 153 
during ScanMove instrument administration as well as reference validated rating scales. These 154 
scales were selected by panelists based on their frequency of routine application, and included 155 
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the Modified Simpson Angus Scale (MSAS) for parkinsonism,
23
 the Abnormal Involuntary 156 
Movements Scale (AIMS) for dyskinesia and adventitious movements,
22
 and the Barnes 157 
Akathisia Rating Scale (BARS) for akathisia.
24
 The MSAS is a 10-item scale in which each item 158 
is scored from 0 to 4; the total score is obtained dividing by 10 the sum of the scores of the 10 159 
items, therefore ranging between 0 and 4. A revised version of this scoring was also used for 160 
analysis, which omitted items 7 and 10, judged by the panel not specifically relevant to 161 
parkinsonism. For this revised version the total score was obtained, dividing the sum of the 162 
scores of the retained by 8, hence leaving the total score range of 0-4 unchanged. Only the first 7 163 
items of the AIMS were used for analysis; these are scored 0=absent to 4=severe, yielding a total 164 
score range of 0-28. The BARS uses three questions with response ratings from 0=absent to 165 
3=severe; these are summed to give a score ranging between 0 and 9; only the global scale was 166 
used in the analysis, dichotomised to those scoring >2 (defining ‘clinically relevant’ akathisia) 167 
versus those scoring less than 2. The overall duration of scale administration ranged between 10 168 
and 15 minutes.  169 
Nurses and evaluating neurologist entered their evaluation on a web-based database, 170 
remaining blinded to each other’s ratings for the study duration. The web-based database, built 171 
using Sealed Envelope, included range, logic and consistency checks and, for closed questions, 172 
provided a number of fixed options, all of which minimised data entry errors. Data were further 173 
checked by the main statistician in the study team (LM) who then liaised with the study 174 
coordinator (DM) to rectify pending issues with illegal values or inconsistent data entered.  175 
Statistical analyses 176 
Descriptive statistics were calculated for all variables, items within the measures, their total 177 
scores and the ScanMove instrument. Any systematic difference between raters on the 30 178 
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patients’ video-recordings was estimated through an interaction test in a model with repeated 179 
patient measures. For the same video-recordings, the relationship of positive detection between 180 
nurses and neurologist was estimated in non-linear models with repeated measures for raters to 181 
estimate the diagnostic odds ratio (OR). The diagnostic OR is the ratio of the odds of the test 182 
being positive if the subject has a disease relative to the odds of the test being positive if the 183 
subject does not have the disease. As this is estimated using mixed models to account for rater, 184 
the confidence interval on the diagnostic OR accounts for the between and within rater 185 
variability. 186 
To test criterion validity of the nurse-based dichotomous judgement on the 187 
presence/absence of parkinsonism, hyperkinesia and akathisia derived from the ScanMove 188 
instrument (>1 item= presence), we calculated the area under the curve, along with sensitivity, 189 
specificity and percentage correctly identified and their respective 95% confidence intervals, 190 
using as gold standard the neurologist’s dichotomous judgement based on the ScanMove 191 
instrument.  192 
For concurrent validity analysis of the nurses’ ScanMove additive score, mixed effect 193 
linear (for MSAS and AIMS as outcome measure) or logistic (for BARS as outcome measure) 194 
regression models were used, accounting for differential rating across nurses with a random 195 
intercept. For these models, “unsure” ratings in the ScanMove instrument were recoded to “no”. 196 
Gold standard scale scores were calculated for the original of each scale, as well as for the 197 
revised version of MSAS. The revised version of MSAS was also used to assess first order 198 
interactions between ScanMove items; these were considered using backwards selection, based 199 
upon a criterion for model entry of p<0.20. There was no interaction analysis for BARS Positive 200 
scores. Models within each outcome measure were compared using the Akaike information 201 
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criterion (AIC),
30
 for which the best fitting model is the one with the lowest AIC. Once the best 202 
fitting models were established for MSAS and AIMS, the fitted values (fixed effect+contribution 203 
for the random effect) were plotted against the actual scores. Finally, Bland-Altman plots were 204 
constructed.
31
 For the BARS models, the area under the curve was calculated along with the 205 
sensitivity, specificity and percentage correctly identified and their respective 95% confidence 206 
intervals. Analyses used Stata version 14.2 (College Station, TX: StataCorp LP) or SAS version 207 
9.4 (SAS Institute, Cary NC). 208 
The ScanMove study was approved by the NRES Ethics Committee London – Bromley 209 
Authority (authorization nr. 14/LO/0835). 210 
 211 
Results 212 
Content validity 213 
The content validity testing led to the selection of 31 clinical features diagnostically relevant for 214 
MD screening (11 for parkinsonism, 14 for hyperkinesia, 6 for akathisia). The new screening 215 
procedure was subsequently operationalised into a checklist of 38 questions that captured the 216 
outcome for each of the 31 features (Table 1).  217 
Reliability assessment 218 
The neurologist’s judgement on the 30 video-recorded patients identified parkinsonism in 22, 219 
hyperkinesia in 28 and akathisia in 4. There was no systematic difference between the 10 nurses 220 
in their prediction of any MD category (parkinsonism p=0.65; hyperkinesia and akathisia 221 
p=0.99). The diagnostic ORs expressing the relationship between nurses’ and neurologist’s 222 
dichotomous judgement on the same 30 video-recordings were 6.75 (95%CI 3.3-13.8, p=0.0002) 223 
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for parkinsonism, 8.60 (95%CI 3.5-21, p=0.0004) for hyperkinesia, and 32.7 (95%CI 11.4-94.1, 224 
p<0.0001) for akathisia.  225 
Feasibility 226 
The ScanMove instrument demonstrated good feasibility. Data collection could be terminated in 227 
635 of 647 patients recruited. Twelve (1.8%) dropped out during data collection due to 228 
insufficient compliance: 5 (0.8%) did not comply during the ScanMove procedure and 7 (1.08%) 229 
dropped out during the neurologist’s procedure. The duration of administration ranged between 230 
12 and 17 minutes, although it was kept below 15 minutes in 95% of the assessments; the 231 
duration of administration did not significantly differ across nurses (data not shown). 232 
Criterion validity 233 
The majority of the 635 participants were male (70%), with a mean age of 45 years (SD 12; 234 
Table 2). Just under half of participants were white (49%) and 30% were Asian.  Just over 80% 235 
of participants had a primary diagnosis of schizophrenia. The most frequently used antipsychotic 236 
was clozapine (45%), followed by risperidone (30%), olanzapine (24%) and aripiprazole (21%); 237 
38% of patients had been exposed to anticholinergic drugs.  238 
From the nurses’ rating using the ScanMove instrument (Table 1), the most common item 239 
detected was ‘abnormal limb movements’ (62%), followed by ‘reduced arm swing’ (55%), 240 
‘reduced amplitude’ and ‘reduced speed’ on finger tapping (53%), and ‘reduced speed’ on foot 241 
tapping (38%); the least common clinical feature was ‘rising out of a chair despite being asked to 242 
sit’ (1%). 243 
Using the most lenient >1 item cut-off, a ScanMove instrument-based diagnosis of any of 244 
the three movement disorders categories explored was formulated by nurses for 598 patients 245 
(94%), and by the neurologist for 585 (92%). Seventy-five (11.8%) and 111 (17.4%) patients 246 
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were judged to manifest all three categories of movement disorders by nurses and by the 247 
neurologist, respectively. A diagnosis of parkinsonism was formulated by the nurse using the 248 
ScanMove instrument in 502 (79%) patients. The neurologist identified parkinsonism with the 249 
ScanMove instrument in 305 (48%) of patients. Compared to the ScanMove neurologist 250 
judgment, the ScanMove nurse judgement showed high sensitivity (90.1%), but low specificity 251 
(30.7%), and the area under the curve (C statistic) was 0.60 (95% CI 0.57-0.63). Hyperkinesia 252 
was diagnosed in 515 (81%) patients by the nurse using the ScanMove instrument. The 253 
neurologist identified hyperkinesia with the ScanMove instrument in 528/636 (83%) patients. 254 
The ScanMove nurse judgement showed a sensitivity of 88.8%, but a lower specificity of 58.5%, 255 
with an area under the curve of 0.74 (95% CI 0.69-0.79). Finally, akathisia was diagnosed in 256 
134/636 (21%) patients by the nurse using the ScanMove instrument. The neurologist identified 257 
akathisia in 184/636 (29%) patients using the ScanMove instrument, and in 155/636 (24.4%) 258 
patients using the cut-off score of 2 on the BARS. The ScanMove nurse judgement showed low 259 
sensitivity (38.3%), but greater specificity (86.3%); the area under the curve was 0.62 (95% CI 260 
0.58-0.66).  261 
Applying a more restrictive cut-off of >2 items to the diagnosis of parkinsonism and 262 
hyperkinesia led to an increase in specificity (from 23.5% to 56.8% for parkinsonism; from 263 
58.5% to 83.4% for hyperkinesia), but with a decrease in sensitivity (from 93.6% to 65.2% for 264 
parkinsonism; from 88.8% to 56.5% for hyperkinesia).  265 
Concurrent validity 266 
From the neurologist’s rating (Supplementary Table 1), the median overall score of the MSAS 267 
was 0.20 (interquartile range [IQR] 0.10, 0.40) for the original 10-item version, and 0.13 (IQR 268 
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0.00, 0.38) for the revised 8-item version. The overall median AIMS score using the first seven 269 
items only was 0 (IQR 0, 4). A quarter of participants were BARS (akathisia) positive.   270 
The mixed effects linear regression model in which the ScanMove score best predicted 271 
the revised MSAS score with interactions included all 11 parkinsonism-specific ScanMove items 272 
(Supplementary Table 2). The ScanMove item that made the greatest contribution to the MSAS 273 
in all models without interactions was the muscle tone assessment (item 33). However, when the 274 
fitted values were plotted against MSAS scores, no obvious relationship between the actual 275 
scores on the revised MSAS and the fitted values from the model was seen. The Bland Altman 276 
plot yielded a mean±SD difference of -1.59x10
-9
±0.26 and 95% limits of agreement of -5 to 5, 277 
indicating low agreement between MSAS score and fitted values.  278 
Similar findings were obtained for AIMS score as outcome. The mixed effects linear 279 
regression model in which the ScanMove score best predicts the AIMS score with interactions 280 
included all 14 hyperkinesia-specific ScanMove items (Supplementary Table 3). When the fitted 281 
values from the model were plotted against AIMS score, no obvious relationship was seen. The 282 
Bland Altman plot yielded a mean±SD difference of 5.65x10
-9
±2.7, and 95% limits of agreement 283 
of -5 to 5, also indicating low agreement between AIMS score and fitted values.  284 
The mixed effects logistic regression model in which the ScanMove score best predicted 285 
the BARS dichotomous outcome included all 6 akathisia-specific ScanMove items. Of note, 286 
some of these items were reported in a low number of participants (Table 1). The area under the 287 
curve for the best fitting model (Supplementary Table 4) was 0.72 (95% CI 0.67-0.77). For this 288 
model the optimum sensitivity was 63.8% (95% CI 55.6%-71.4%) and specificity 67.8% (95% 289 
CI 63.4%-72.1%). 290 
 291 
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Discussion 292 
In this study we developed a screening tool (ScanMove instrument) for MD in patients with 293 
established psychosis, conceived for use by MH nurses. Item selection and operationalization 294 
were conducted by a multidisciplinary panel of MD neurologists, psychiatrists with extensive 295 
clinical experience of such MD, and a MH nurse. Clinical features judged to be diagnostically 296 
relevant for parkinsonism, hyperkinesia and akathisia were assessed across different functional 297 
states or body locations, in order to optimise the sensitivity of the instrument.  298 
 The ScanMove instrument administered by the MD neurologist identified at least one of 299 
the three MD categories in 92% of the 635 screened community patients with psychosis. This 300 
frequency was very similar to the one obtained by MH nurses using the same instrument. 301 
Although it is likely that only a subgroup of these patients will require therapeutic intervention 302 
for their MD, the frequency estimates obtained using our screening instrument support the need 303 
for greater attention on MD from MH professionals, at least in this type of community-dwelling 304 
patients with established psychosis.  305 
Inter-rater reliability analysis did not identify any systematic difference between raters on 306 
the scores for each MD category. An important limitation of this analysis is that the direct 307 
muscle tone assessment of rigidity could not be performed using video-recordings. Throughout 308 
field validity testing, the ScanMove instrument showed high feasibility, with a small number of 309 
missing values and a narrow range of administration time that was consistent with the 310 
developers’ aim.   311 
Our criterion validity analysis showed that the dichotomous diagnostic judgement using 312 
the most lenient cut-off (>1 item for each diagnostic category) was moderately to highly 313 
sensitive, but not specific, in diagnosing parkinsonism and hyperkinesia, when compared to the 314 
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neurologist’s dichotomous judgement. When a more restrictive cut-off of >2 items was used to 315 
define positive detection of parkinsonism or hyperkinesia, the ScanMove instrument improved in 316 
specificity, but at the cost of lower sensitivity, diminishing its value as a screening instrument. 317 
Based on this sensitivity analysis, the nurse-administered ScanMove instrument appears to be 318 
sufficiently accurate in ruling out parkinsonism and hyperkinesia in this patient population. 319 
However, the low specificity values indicate that the diagnoses of parkinsonism and hyperkinesia 320 
obtained using the nurse-administered ScanMove instrument should always be confirmed by a 321 
physician.  322 
Different considerations should be made with respect to akathisia, for which the 323 
diagnostic accuracy of the nurse-administered ScanMove instrument was less satisfactory at the 324 
>1 item cut-off, suggesting limitations in the content of the items specifically related to akathisia 325 
and/or greater training requirements to optimise rating proficiency of akathisia amongst nurses. 326 
For concurrent validity testing, we evaluated how the ScanMove instrument predicts the 327 
outcome of a comprehensive reference procedure yielding a severity score for parkinsonism and 328 
hyperkinesia and a binary outcome for akathisia. The composition of this reference procedure 329 
aimed to reproduce, to the best of our abilities, the standard practice of psychiatrists working in 330 
the UK National Health Service. Importantly, the AIMS evaluates all hyperkinesia with the 331 
exception of tremor, which was detected in 47% of patients by item 8 of the MSAS, and 332 
contributed substantially to the 83% frequency of hyperkinesia detected by the neurologist’s 333 
dichotomous judgement. Our results showed that the ScanMove instrument does not yield 334 
quantitative scores that are useful to predict the scores on our reference instruments. With respect 335 
to parkinsonism and hyperkinesia, this finding can partly be explained by important differences 336 
in their content between the ScanMove instrument and the MSAS and AIMS. The assessment of 337 
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parkinsonism using MSAS is skewed towards rigidity and tremor, without taking bradykinesia 338 
into account. Instead, in the ScanMove instrument, tremor contributes to the hyperkinesia score, 339 
and bradykinesia is included among the items characterizing parkinsonism. Not surprisingly, the 340 
ScanMove item that contributed most to the prediction of the MSAS score was the one 341 
examining rigidity.  342 
When delivered by MH nurses, the ScanMove instrument could provide the capability to 343 
increase the proportion of patients assessed for MD with a minimal increase in costs to the 344 
services. Assuming that screening is conducted by a MH nurse, the cost for the 15 minutes of 345 
patient contact required to conduct the screen is £9.25 in 2016 GBP.
32
 Across 1,000 patients and 346 
using the prevalence, sensitivity and specificity for hyperkinesia, for example, the total cost of a 347 
MH nurse using ScanMove would be £9,250. Based on observations from our sample, 808 348 
patients of the 1,000 would be identified as potentially having hyperkinesia and referred to the 349 
Consultant Psychiatrist for further assessment (5 minutes review of notes and 15 minutes for 350 
ScanMove), for a total cost of £29,073 for the Consultant Psychiatrist assessment, and a cost of 351 
£38,323 in total. If current practice of the 30 minutes assessment by a Consultant Psychiatrist at a 352 
cost of £54 was to be conducted for the same 1,000 patients, the total cost would be £54,000. As 353 
a result, ScanMove presents a feasible and lower cost way to increase yearly screening of 354 
patients for MD, plus referral and treatment. 355 
In conclusion, the MH nurse-administered ScanMove instrument demonstrated good 356 
feasibility and inter-rater reliability and acceptable sensitivity as screening tool for parkinsonism 357 
and hyperkinesia in patients with established psychosis. Sensitivity for akathisia was less 358 
satisfactory. In routine clinical practice, it may represent a useful aid in the selection of those 359 
patients warranting review by a physician for the management of these motor manifestations. 360 
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Further work is needed to evaluate whether a more extensive training programme for MH nurses 361 
in the ScanMove instrument might increase its overall specificity, or its sensitivity for the 362 
diagnosis of akathisia. With regard the latter, using the tool in combination with the BARS may 363 
be an option, though the BARS has not been validated as yet for MH nurse use. Alternatively, 364 
future work could aim at a revised content for the akathisia items to improve this specific aspect 365 
of the ScanMove tool. 366 
Cost-effectiveness appears promising, but requires further investigation. In order to 367 
support its dissemination and implementation, future research should compare the cost-368 
effectiveness and the impact on management decision-making and quality of life of use of the 369 
ScanMove instrument compared to routine standards of care.   370 
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Table 1. Item per item frequency distribution of movement disorders characteristics detected 
by the nurse-administered ScanMove instrument.  
ScanMove instrument item n % 
1. When walking Is the arm swing reduced (even on one side only)? 350 55 
2. When walking Is the stride length reduced (even on one side only)? 126 20 
3. When walking Does the patient shuffle his/her feet? 88 14 
4. Does the patient walk with a stooped trunk? 112 18 
5. When walking Is the patient’s head tilting back or to one side? 35 6 
6. When walking Do you notice any abnormal movements of the face (such as grimacing, 
pursing and smacking of the lips, chewing and lateral movements of the jaw, tongue 
protrusion)? 
82 13 
7. When walking Do you notice any abnormal movements of the limbs (such as shaking, 
twitching or twisting of hands or feet)? 
111 18 
9. When standing Does the patient have any purposeless movements of the legs, such as 
marching or stamping movements, walking on-the-spot, twitchy, jerky movements? 
73 12 
10. When standing Does the patient’s body keep rocking side to side? 43 7 
11. When standing Does the patient keep pacing around the room leaving his/her spot 
despite the instruction to stand still? 
14 2 
13. When standing Is the patient’s head tilting back or to one side? 36 6 
14. When standing Do you notice any abnormal movements of the face (such as 
grimacing, pursing and smacking of the lips, chewing and lateral movements of the jaw, 
tongue protrusion)? 
114 18 
15. When standing Do you notice any abnormal movements of the limbs (such as shaking, 
twitching or twisting of hands or feet)? 
200 31 
17. When sitting Does the patient have any purposeless movements of the legs, such as 
shuffling, jiggling, trampling of the legs? 
54 9 
18. When sitting Does the patient get up out of the chair despite the instruction to sit 
down? 
5 1 
20. When sitting Is the patient’s head tilting back or to one side? 42 7 
21. When sitting Do you notice any abnormal movements of the face (such as grimacing, 
pursing and smacking of the lips, chewing and lateral movements of the jaw, tongue 
protrusion)? 
142 22 
22. When sitting Do you notice any abnormal movements of the limbs (such as shaking, 
twitching or twisting of hands or feet)? 
200 31 
24. When sitting Does the patient’s body keep rocking side to side? 15 2 
25. Do the patient’s finger tapping movements become smaller as he/she carries on with 
the task? 
338 53 
26. If yes, does the patient’s finger tapping become also slower as he/she carries on with 
the task? 
243 38 
27. Do the patient’s foot tapping movements become smaller as he/she carries on with the 
task? 
181 29 
28. If yes, does the patient’s foot tapping become also slower as he/she carries on with 
the task? 
144 23 
29. While keeping mouth open Do you notice any abnormal movements in the face (such 
as grimacing, pursing and smacking of the lips, chewing and lateral movements of the 
jaw, tongue protrusion)?  
143 23 
31. While keeping mouth open Do you notice any excessive pooling of saliva in the mouth, 
or is there any drooling of saliva outside of his/her mouth? 
22 3 
32. Is his/her voice excessively soft? 31 5 
33. With the patient relaxed and not actively contracting his/her muscles, do you feel any 
resistance while doing these manoeuvres? 
141 22 
34. While holding arms outstretched or in front of chest with each elbow out to the side 
Is the patient’s head tilting back or to one side? 
28 4 
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Table 2. Summary of demographic and clinical characteristics of the clinical sample for the 
field validation of the ScanMove instrument. GCSE: General Certificate of Secondary 
Education (usually achieved at age 16); A level: Advanced level (usually achieved at age 18); 
NVQ: National Vocation Qualification (usually achieved at age 19); HNC: Higher National 
Certificate / HND: Higher National Diploma (usually achieved at age 22). IQR: Interquartile 
Range.  
Variable n % 
Male gender 443 70 
Ethnicity   
White 312 49 
Black 68 11 
Asian 191 30 
Other 64 10 
Highest educational attainment   
No qualifications 179 28 
GCSE or equivalent 163 26 
A Level or equivalent 92 14 
NVQ or equivalent 53 8 
HNC/ HND or equivalent 27 4 
Degree 66 10 
Higher degree 31 5 
Other 24 4 
Years of education median (IQR) 12 (11, 15) 
Primary diagnosis   
Schizophrenia 521 82 
Schizophreniform disorder 3 0.5 
Schizoaffective disorder 92 14 
Delusional disorder 19 3 
Secondary diagnosis 173/615 28 
Antipsychotic drug  Number ever 
exposed/total number of 
participants 
% 
Amisulpride 88 14 
Aripiprazole 130 21 
Chlorpromazine 28 4 
Clozapine 285 45 
Flupentixol 81 13 
Flupentixol decanoate 7 1 
Fluphenazine 6 1 
Fluphenazine decanoate 9 1 
Haloperidol 103 16 
Haloperidol decanoate 9 1 
Levomeprazine 2 0.3 
Olanzapine 154 24 
Paliperidone 27 4 
Pipotiazine palmitate 23 4 
Prochlorperazine 1 0.2 
Quetiapine 63 10 
Risperidone 191 30 
Sulpiride 33 5 
Thioridazine 1 0.2 
Trifluoperazine 3 0.5 
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Zuclopenthixol 100 16 
Zuclopenthixol decanoate 15 2 
Anticholinergics 240 38 
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